Novavax Partners with Sanofi on Flu/COVID-19 Vaccine
Ticker: NVAX · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1000694
| Field | Detail |
|---|---|
| Company | Novavax Inc (NVAX) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, vaccine-development, partnership
Related Tickers: SNY
TL;DR
Novavax teams up with Sanofi for a combo flu/COVID shot using Novavax's adjuvant tech.
AI Summary
On October 2, 2024, Novavax, Inc. announced a new collaboration with Sanofi to develop and commercialize a combination vaccine for influenza and COVID-19. This partnership aims to leverage Novavax's Matrix-M adjuvant technology with Sanofi's influenza vaccine expertise.
Why It Matters
This collaboration could lead to a more convenient, single-dose vaccine for multiple respiratory illnesses, potentially increasing vaccination rates and simplifying public health efforts.
Risk Assessment
Risk Level: medium — The success of this collaboration depends on the complex development and regulatory approval process for a novel combination vaccine.
Key Players & Entities
- Novavax, Inc. (company) — Registrant
- Sanofi (company) — Collaborator
- October 2, 2024 (date) — Event Date
- Matrix-M (technology) — Novavax's adjuvant technology
FAQ
What is the primary goal of the collaboration between Novavax and Sanofi?
The primary goal is to develop and commercialize a combination vaccine for influenza and COVID-19.
What specific technology from Novavax will be utilized in the new vaccine?
Novavax's Matrix-M adjuvant technology will be utilized.
What is Sanofi's area of expertise that will be leveraged?
Sanofi's expertise in influenza vaccines will be leveraged.
When was the earliest event reported in this Form 8-K?
The earliest event reported was on October 2, 2024.
What is the principal executive office address for Novavax, Inc.?
The address is 700 Quince Orchard Road, Gaithersburg, Maryland 20878.
Filing Stats: 1,230 words · 5 min read · ~4 pages · Grade level 14.7 · Accepted 2024-10-02 18:28:57
Key Financial Figures
- $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
Filing Documents
- tm2425496d1_8k.htm (8-K) — 31KB
- 0001104659-24-105533.txt ( ) — 200KB
- nvax-20241002.xsd (EX-101.SCH) — 3KB
- nvax-20241002_lab.xml (EX-101.LAB) — 33KB
- nvax-20241002_pre.xml (EX-101.PRE) — 22KB
- tm2425496d1_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Novavax, Inc. ("Novavax") is aware of an analyst report published on October 1, 2024, which referred to discussions with Novavax's management regarding, among other things, the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season. Novavax would like to clarify that while it has anticipated the COVID-19 vaccination market in the U.S. will be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance issued on August 8, 2024. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements, including statements related to the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season. Generally, forward-looking statements can be identified through the use of words or phrases such as "believe," "may," "could," "will," "would," "possible," "can," "estimate," "continue," "ongoing," "consider," "anticipate," "intend," "seek," "plan," "project," "expect," "should," "would," "aim," or "assume," the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking beliefs and expectations about the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements. These risks and uncertainties include, without limitation, Novavax's and Sanofi Pasteur, Inc.'s ("Sanofi's") ability to successfully impleme
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVAVAX, INC. Date: October 2, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary